GhanaReview International - The Leading Ghanaian News Agency
London New York Accra
GRi Latest News
Sunday 24 November 2024

2021-04-07

[N] As Majority Leader be circumspect with your utterances

2021-03-19

[I] Goldman Sachs staff revolt at ‘98-hour week’
[I] Over half of staff go back to workplace
[I] Health chiefs confirm Oxford-AstraZeneca Covid jab safe to use
[S] Kotoko Signs Second Brazalian Player
[N] It Is A Blatant Lie That I’ve Declared My Prez Ambition-Agric Minister
[S] Accra Mayor to change face of sports in Greater Accra
[S] Ambassador Lutterodt charges GOC prez to tackle Martha Bissah issue
[S] Ben Nunoo-Mensah hits ground running for GOC
[S] Black Stars to Engage Uzbekistan In International Friendly
[N] House of Chiefs calls for collaboration with MMDCEs for development
[N] Baby Harvesting: More suspects picked
[N] Police pledge commitment to bringing Sheikh Maikano’s murderers to book
[B] ARB Apex Bank admitted to Ghana-Sweden Chamber of Commerce
[N] Desist from starting race ahead of time - Obiri Boahen to NPP presidential
[N] Gov’t announces construction of five interchanges in Ashanti
[N] Controversial textbooks: NPP urges NaCCA to enforce rules without fear or favour
[N] Staff working on Tamale interchange call off strike
[N] Newly proposed taxes a huge hindrance to businesses’ recovery
[N] Government can’t take a unilateral decision on salaries for public workers
[N] Ghana records 2 new Covid-19 variants; experts call for immediate action

2021-03-17

[S] First GFA safety and security seminar takes place today
[B] NDPC holds consultation medium term framework for 2022-2025 in Oti
[B] More investments recorded in Western Region despite COVID-19
[N] Ghana records 698 COVID-19 deaths
[N] NDC’s Ofosu Ampofo behaves like a toddler – Allotey Jacobs
[S] Don’t tax sports betting, ban it – Ato Forson to government
[N] Ama Benyiwaa Doe slams Allotey Jacobs; says he has no influence
[N] Approving Akufo-Addo’s ministers ‘regrettable and unfortunate’ – NDC caucus
[S] Don't rush Satellites players, warns GFA coaching boss
[N] Eastern Regional Hospital detains 246 patients for non-settlement of bills
[N] COVID-19 vaccination in Ghana: 1,000 reports received on adverse effects
[N] Ignore reports of rift between local, foreign staff at AfCFTA secretariat – Govt
[N] Remain calm, support our leadership in Parliament – NDC Council of Elders
[N] Ghana hasn’t recorded any case of blood clots from COVID-19 vaccination – FDA
[N] 9-year-old boy burnt to death as stepfather sets house ablaze
[B] Budget cuts for legislature, judiciary won’t be entertained – Speaker
[I] Half of UK managers back mandatory Covid vaccines for office work
[I] Brussels to propose Covid certificate to allow EU-wide travel

2021-03-16

[I] Nick Candy leads £1m drive to oust London mayor Sadiq Khan
... go Back
 
International

[ 2021-02-25 ]

US set to approve Johnson & Johnson’s single dose Covid vaccine
A single-dose Covid-19 vaccine is set to receive
approval in the US as soon as Friday after proving
safe and effective in trials, showing complete
protection against hospitalisation and death.

The Johnson & Johnson vaccine is 85 per cent
effective at preventing severe illness and 66 per
cent protective overall against moderate cases,
experts from the US Food and Drug Administration
confirmed today.

The vaccine produced by the US pharmaceutical
giant has advantages over its rivals because it
can be kept in a fridge for three months, making
it easier to store and distribute than
alternatives made by Pfizer and Moderna which must
be kept frozen until use. The single-jab regime
means there is no need for follow-up
appointments.

American regulators have so far authorised two
double-dose vaccines, made by Pfizer-BioNTech and
Moderna. AstraZeneca, which is approved in Europe
and Israel, said this week that it expects its
two-jab vaccine to receive US authorisation at the
start of April once it has completed and analysed
a large-scale trial involving 30,000 people.

The FDA’s panel of independent experts meets on
Friday to decide on approving the Johnson &
Johnson product.

“We know this vaccine prevents 85 per cent of
the severe disease. It was 100 per cent effective
in preventing hospitalisation and deaths, and
that’s really what’s important,” Nancy
Bennett, a professor of medicine and public health
sciences at the University of Rochester School of
Medicine and Dentistry, told The Washington Post.

Crucially J&J reported to the FDA that its data
suggested its vaccine was effective at preventing
asymptomatic infections. In a preliminary analysis
of its trial it found 16 cases of asymptomatic
cases in the placebo group versus just two in the
vaccine group, or an 88 per cent efficacy rate.
The reduction of asymptomatic cases implies that
the vaccine can cut transmission of the disease.

J&J’s vaccine was 66 per cent effective in
preventing Covid-19 against several main variants
in a global trial involving nearly 44,000 people,
the company said last month.

Its effectiveness varied from 72 per cent in the
United States to 66 per cent in Latin America and
57 per cent in South Africa. Overall the vaccine
was 85 per cent effective in stopping severe cases
of the disease and not one vaccinated person in
the trial died from Covid-19.

SPONSORED


Fourteen days after injection two vaccine
recipients developed Covid-19 severe enough to
require medical treatment, compared with 14 in the
placebo group. After 28 days no vaccine recipients
developed Covid-19 severe enough to require
medical intervention.

Three vaccine recipients had severe side effects
in the trial that were probably related to the
vaccine but the FDA said its analysis did not
raise any specific safety concerns that would rule
out an emergency use authorisation.

The vaccine was less effective in a group of
adults older than 60 who also had risk factors for
severe illness but regulators said that there were
no deaths or cases requiring medical intervention
a month after those older adults received
vaccines. There were seven deaths in the trial,
all in the group that received a placebo.

Trials showed that a full course of the
Pfizer-BioNTech vaccine was 95 per cent effective
in protecting against Covid-19 and Moderna 92 per
cent.

J&J was on track to become the world’s first
one-dose option until Mexico announced this month
it would use a one-dose version from China’s
CanSino. That vaccine is made with similar
technology as J&J’s but was initially developed
as a two-dose option.

If the FDA clears the J&J vaccine for US use only
a few million doses are expected to be ready for
shipping in the first week after approval. J&J
told Congress this week that it expected to
provide 20 million doses by the end of March and
100 million by summer.

European regulators and the World Health
Organisation are considering J&J’s vaccine.
Worldwide, the company aims to produce around a
billion doses by the end of the year.

Source - The Times, UK



... go Back

 
Add YOUR View here

Ghana Review International (GRi) is published by Micromedia Consultants Ltd. T/A MCL - a wholly Ghanaian owned news agency. GRi is an independent publication and is non-aligned to any political party or interest group, within or outside of Ghana. It is a reliable source of information for Ghanaians and non-Ghanaians alike. This magazine will be of interest to any person with an interest in Ghana, Ghanaians and Africans, wherever in the world they live. This website is the on-line arm of the publication. It contains news and reviews on Ghana and the international communities.

All pages are © Copyright Ghana Review International (GRi) 1994 - 2021